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1. Introduction  
Liver cirrhosis is the final stage of various chronic liver diseases. The concept is essentially 
morphological, defined as a diffuse alteration of hepatic architecture by the presence of 
necrosis, fibrosis and regenerative nodules. These disorders conduct to intrahepatic vascular 
changes and to the reduction of functional mass. Finally, the consequences are the 
development of portal hypertension and the occurrence of liver failure. (Ampurdanés S, 
2002) 
For many decades, alcohol was considered the leading cause of cirrhosis. But actually, viral 
hepatitis by viruses B (HBV) and C (HCV) are recognized as the most important sources. 
(Mandayam S) Another common cause is Nonalcoholic Fatty Liver Disease (NAFLD), 
followed by autoimmune diseases with or without cholestasis, among others. 
1.1 Natural history of liver cirrhosis and its complications 
The studies that provide more data on the natural history of cirrhosis are related to the 
evolution of chronic hepatitis by HBV and HCV. These are based on prospective, 
retrospective and cross studies, but are conditioned by factors that make difficult to 
establish absolute evidence on the natural history of the disease. (Serra MA., 2006) 
Of those patients with HCV, 50% usually develop chronic liver disease including cirrhosis 
and liver cancer. It is estimated that 15% of chronically infected persons develop liver 
cirrhosis within 20 years. (Wiese M, 2005) However, there are individual differences. 
Currently it is known that 33% of patients develop cirrhosis in less than 20 years, while 
another 31% will need many more years in order to develop the same damage. (Serra MA 
2006) 
Usually it is a silent disease. Most patients are asymptomatic or have nonspecific symptoms 
until decompensation occurs. They can start with symptoms related to complications of liver 
failure or portal hypertension. 
Ascites is the most common complication and of earlier onset. Once patients with cirrhosis 
develop ascites the prognosis worsens. It is estimated that approximately 50% of them could 
die within two years if they do not have a transplant. So, this is a major criterion for liver 
transplant evaluation in the United States and Europe. (Settle 2004, Sagnelli 2005) 
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Along with ascites, there may be other serious complication such as spontaneous bacterial 
peritonitis. In these cases, the probability of survival one year after this complication 
appears is only 40%. This is a strong reason for evaluating these patients as candidates for 
transplantation. (Corrao 1997) Similarly, other complications may appear such as hepatic 
encephalopathy and hepatic-renal syndrome. Both also worsen the prognosis. (Mandaya 
2004)  
Variceal hemorrhage occurs in 30 to 40% of patients with liver cirrhosis. In the past two 
decades, even with the improvement achieved in the treatment and in the prognosis after 
bleeding, mortality at six weeks is still high. It is estimated between 15 and 30% in patients 
with stage C of Child-Pugh. (Hands 2008)  
After a first episode of hepatic encephalopathy the survival of cirrhotic patients is 42% in the 
first year, and 23% in the following three years. (Mendez-Sanchez 2005) 
Hepatocellular carcinoma is another major complication and can occur at any stage of 
cirrhosis. It is recognized as the leading cause of death in the compensated phase, especially 
in patients with HCV. (Capocaccia R, 2007; Perz, J.F, 2006) 
1.2 Indication of liver transplantation and survival models 
Liver transplantation is the treatment of choice in acute and chronic irreversible liver failure 
of different etiologies, in primary liver tumors and when an impaired quality of life appears 
by manifestations of liver disease, as intractable pruritus and hepatic osteodystrophy. 
The most commonly used survival models to assess the degree of liver failure and to 
prioritize patients on the waiting list for liver transplantation are: the Child-Pugh score 
(Oellerich M, 1991) and Model for End Stage Liver Disease (MELD) score (Malinchoc M, 
2000). Although currently used primarily MELD, both have been included among the 
criteria for liver allocation in the United States and Europe (Freeman RB Jr, 2004; Adler M, 
2005). 
The Child-Pugh score has been widely used both in research and in clinical practice. For 
these reason, candidates for liver transplantation were prioritized mainly by these score, 
which included subjective measures of encephalopathy and ascites, and time waiting on the 
list. However, the need for a more accurate system in which the urgency of assignment was 
a relevant criterion, determined the introduction of the MELD score that is also very 
valuable as a predictor of mortality and allocation of organs for patients on the waiting list. 
The MELD score had been previously validated as a predictor of 3-month mortality for 
patients with chronic liver disease. (D'Amico G, 2006; Botta F, 2003)  
The MELD system appears superior for comparing populations and has had a positive 
impact on allocation and survival in liver transplantation; however, it is still far from 
perfect. One of the disadvantage of the MELD formula is the loss of prognostic accuracy in 
periods longer than 3 months. The Child-Pugh classification provides superior results for 
periods exceeding one year. For these reasons, some authors recommend implementing 
both systems. (Forman LM, 2001; D'Amico G, 2006; Prieto M, 2007; Durand F, 2005.) 
The Child-Pugh score evaluates five parameters: ascites, encephalopathy, bilirubin, 
prothrombin time and albumin. Although never formally validated, has been the most 
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widely used for decades. It is easy to apply and has proved useful in estimating the 
prognostic index of survival. But some limitations are pointed out such as, not all variables 
have an independent effect, it includes subjective variables like ascites and encephalopathy, 
the cutoff points for quantitative variables are not optimal, and it does not take into account 
certain important prognostic factors such as renal function. (Oellerich M, 1991; Prieto M, 
2007)  
The MELD model uses a mathematical formula with simple and objective variables such as, 
serum concentrations of bilirubin, creatinine and international normalized ratio (INR) of 
prothrombin time. From these variables, you get a score that is predictive of survival. 
Initially it also included the etiology of the disease, but this variable was excluded because a 
minimal influence was observed. (Vargas V 2003) Nevertheless, its application is less 
practical because of the need of computer systems. One of its major limitations is its 
variability due to changes in creatinine and bilirubin. These parameters can be altered by 
treatment, sepsis or hemolysis. The value of creatinine is often affected by diuretics and 
other factors such as age, sex and body mass, which may introduce a bias independent of 
the severity of liver disease. Moreover, the severity of some medical complications, are not 
well reflected in the MELD score. (Prieto M, 2007; Vargas V, 2003; de la Mata, 2004) 
Research is still going in an effort to improve this mathematical model. Many studies have 
proposed the addition of variables that may be of prognostic significance. Recently it has 
been suggested that the addition of sodium to the MELD formula could improve its 
accuracy. Some studies showed that serum sodium lower than 126 mEq/L is an 
independent predictor of mortality among patients listed for transplantation, and the 
addition of sodium to the MELD score increases its prognostic value. In patients with portal 
hypertension and cirrhosis, hyponatremia may be the earliest harbinger of refractory ascites 
and hepatorenal syndrome, and possibly a more sensitive marker than rising creatinine. 
(Taddei TH, 2007) However, this new formula is also subject to interassay variations, as well 
as the potential manipulation can be generated inadvertently by the use of diuretics. It is 
also unknown if its use can lead to increased mortality by neurological causes. For all this, it 
seems premature to use as long as no data are available for validation in larger groups and 
different cohorts. (Cárdenas A, 2008; Jiang M, 2008) Among the new proposals are to include 
the introduction of the measurement of the Hepatic Venous Pressure Gradient (Taddei TH, 
2007), to include ascites, encephalopathy (Ripoll C, 2005; Stewart CA, 2007), sex (S Huo; 
2007) or exclude the INR (Heuman DM, 2007). But is too premature to make conclusions. 
Recently, a new estimator has been projected: the Cuban model Bioclim. This is a score 
calculated by a mathematical model that evaluates the creatinine and bilirubin biochemical 
parameters. It also takes into account: clinical encephalopathy, ascites and variceal upper 
gastrointestinal bleeding, considering the positive or negative response to treatment. 
Compared with Child-Pugh and MELD, the authors of this model (Vilar E, 2009) concluded 
that Bioclim score seems to have a greater discriminatory power in the short-term survival 
(4 to 12 weeks), intermediate term (24 to 52 weeks) and long-term (104 weeks).  
1.3 Studies of survival and prognostic factors 
In order to improve prognostic models many factors have been studied in relation to the 
survival of patients with liver cirrhosis.  
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In a review of 118 studies conducted by D'Amico (D'Amico G, 2006) the Child-Pugh was 
reported as the best predictor of mortality in cirrhosis, followed by the five components 
measured individually. 
Said (Said A, 2004) noted that in one year follow up of cirrhotic patients, male gender, 
MELD score, Child-Pugh and encephalopathy, were associated with increased mortality. 
Independent predictors were the Child-Pugh and encephalopathy. 
Botta (Botta F, 2003) compared the survival of cirrhotic patients at 6 and 12 months using a 
multivariate analysis including variables of Child-Pugh, MELD and a quantitative test of 
liver function test monoetilglicinexylidide (MEGX). At six months, MEGX, creatinine and 
prothrombin time were disposed as predictive factors of lower survival. The ascites was 
added at 12 months. 
Attia (Attia KA, 2008) reported as independent predictors of mortality in 172 African 
patients with cirrhosis, the Child-Pugh score, MELD index, and creatinine.  
London (London MC, 2007), in a study of 308 cirrhotic patients on the waiting list for liver 
transplantation, described the serum sodium and MELD score as independent predictors of 
survival at 3 and 12 months. 
Samada (Samada M, 2008) conducted a study in 144 patients with liver cirrhosis and 
transplant candidates. The variables associated with lower survival at 12 months were: 
prothrombin time, bilirubin, albumin, cholesterol, serum sodium, sex, history of ascites and 
encephalopathy. Also MELD index and Child-Pugh stages were evaluated. But only the 
Child-Pugh score and spontaneous bacterial peritonitis were independent predictors of 
survival.  
In conclusion we can state that detailed clinical evaluation of patients with liver cirrhosis 
and knowledge of prognostic factors associated with survival, could lead to proper 
management of these patients, the appropriate indication for liver transplantation and 
increased survival. This has been the principal motivation of the present study, in order to 
recognize the prognostic factors for survival in patients with cirrhosis within a three year 
period. 
2. Methods 
We performed a descriptive, prospective, and longitudinal study in 194 patients with liver 
cirrhosis. All were referred to the consultation of hepatology and liver transplantation at 
CIMEQ hospital between January 2004 and April 2011. The sample was composed of 144 
patients who met the following inclusion criteria: diagnosis of liver cirrhosis (confirmed by 
laparoscopy, liver biopsy or ultrasound) and rolling up at least 36 months (three years). 
Patients who underwent liver transplantation during the study period, those who were lost 
to follow-up, died of causes unrelated to liver disease, and those who at the time of 
assessment presented hepatocellular carcinoma, cholangiocarcinoma or other malignancies 
were excluded. Were also excluded four patients with spontaneous bacterial peritonitis and 
hepatorenal syndrome. The frequency of evaluations was determined by clinical assessment 
of patients at least twice a year.  
The confirmation of alcoholic and viral etiology was performed. The surface antigen for 
hepatitis B virus (HBsAg) by UMELISA HBsAg and antibody for HCV by HCV–UMELISA, 
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both produced by the National Center for Immunoassay in Havana, Cuba were 
investigated. HCV infection was confirmed by qualitative PCR (UMELOSA) produced by 
the National Center for Immunoassay in Havana, Cuba. The criterion for toxic alcohol 
intake was: 60 g daily intake for men and 40 g for women over 10 years. (Cavalry J, 2002) 
Patients with HBV or HCV and alcohol were included in the viral etiology, because liver 
damage is increased more by the virus than by alcohol. (Safdar K, 2004) 
2.1 Variables studied 
The variables studied were: 
- Sex and age. 
- Laboratory variables: INR, total bilirubin (normal up to 17μmol/L), albumin (normal 
value 35-48 g/L) and creatinine (normal value up to 123 μmol/L). 
- Presence of esophageal varices: established in present or absence depending on the 
report of the upper digestive tract endoscopy, once these were classified according 
Paguet. (González M, 2007) 
- Variables related to complications of cirrhosis: diagnostic criteria considered for the 
purposes of the study were selected taking into account the complications of the 
cirrhotic disease established AEEH guides. (Berenguer J et al, 2001). 
- Ascites: fluid in the abdominal cavity detected by physical examination and/or 
abdominal ultrasound. We determined the presence of this complication if the patient 
had ascites at the time of assessment or had a history of it. 
- Hepatic encephalopathy: presence of neuropsychiatric disorders that occur in patients 
with severe liver dysfunction. We used this complication if it was present at the time of 
the evaluation or the patient's history, family and clinical summary of the center of 
origin.  
- Upper gastrointestinal bleeding (UGB): presence of hematemesis or melena associated 
with esophageal varices and/or portal gastropathy. We evaluated the history of this 
complication by questioning the patient, the clinical summary sent by the center of 
origin or having been submitted for evaluation. 
- Hepatocellular carcinoma, we sought the presence of hepatocellular carcinoma during 
follow-up by surveillance strategy for this disease in cirrhotic patients. The strategy was 
based monitoring by abdominal ultrasound and determination of serum alpha-
fetoprotein every 6 months (twice a year). 
- Classification of Child-Pugh: used to evaluate the degree of liver failure in patients with 
cirrhosis. It has three stages according to score: A, B, C (see Table 1). (Pugh RNH, 1973) 
- MELD: score used to assess the degree of liver failure and prioritize patients on 
transplant waiting list. The MELD score was calculated according to the original 
formula proposed by the Mayo Clinical group as follows: [9.57 × loge creatinine mg/dL 
+ 3.78 × loge bilirubin mg/dL + 11.20 × loge INR + 6.43 (constant for liver disease 
etiology)]. (Kamath PS, 2001) 
- Compensated liver cirrhosis: patients with or without varices but who have not showed 
any of the complications of cirrhosis. 
- Decompensated liver cirrhosis: defined by the presence of ascites, variceal bleeding, 
encephalopathy and/or jaundice. (Gines P, 1987) 
- Survival time: defined from the first assessment in consultation until the date the study 
was closed. 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
130 
 Child-Pugh classification 
Parameter A B C 
Ascites none  slight-moderate tense 
Hepatic encephalopathy (grade)  none  I-II  III-IV 
Serum bilirubin (μmol/L) <51  51-102 >102 
Serum albumin (g/L)  >34  25-34  <25 
Prothrombin time (%)  >60  46-60  <46 
Score  5 to 6 7 to 9 10 to 15 
The total score classifies patients into grade A, B, or C (ordinal scale) according to the points on 
continuous 5-15-point scale, which depends on ascites, encephalopathy, jaundice, serum albumin, and 
prothrombin time prolongation(Pugh RNH, 1973) 
Table 1. Child-Pugh classification for the survival prognosis in liver cirrhosis 
2.2 Statistical analysis 
The data were processed using SPSS 13.0 for Windows. The results are presented as means ± 
standard deviations and confidence intervals of 95% for quantitative variables and as 
percentages for categorical variables. For comparison of continuous variables the t test 
comparison of independent means and chi-square test to compare categorical variables was 
used. Survival analysis was performed using the Kaplan-Meier curves; we used the cutoff 
points at 36 months (three years). We performed a Cox regression analysis to estimate the 
independent effects of potential predictors of survival that had been significant in univariate 
analysis. For all tests a significant level of 0.05 was set. 
3. Results 
Of the 144 patients, 94 (65.2%) were male and 50 (34.7%) females. Everyone had a minimal 
follow up of 36 months with a mean of 43.27 ± 12.97, minimum of three months for those 
who died and up to 73 months for the rest. 
The average age was 47.8 years with a standard deviation of 12.9. Younger age was 18 years 
old and the oldest 87. The group with the highest number was between 40 and 60 years old 
with 84 patients (58.35%) as shown in Table 2. 
 
All patients 144 
Follow-up time (months) 43.27 ± 12.97 (3-73) 
Sex (Male/Female) 94/50 
Age (years) 47.8 ± 12.97 (18-87) 
<40 years 33 (22.9%) 
40–60 years 84 (58.3%) 
>60 years 27 (18.8%) 
Table 2. Baseline characteristics of all patients 
The most common cause of cirrhosis in the study was HCV (42 patients, 29.1%), followed by 
alcohol (33 patients, 22.9%). The group "others" (46 patients, 31.9%) involved autoimmune 
hepatitis, primary biliary cirrhosis, sclerosing cholangitis, Wilson's disease, congenital 
hepatic fibrosis and cryptogenic (Table 3).  
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Etiology of cirrhosis Patients 
Alcohol 33 (22.92%) 
Hepatitis C virus 42 (29.17%) 
Hepatitis B virus 23 (15.97%) 
Others 46 (31.94%) 
Total 144 (100%) 
Table 3. Etiology of cirrhosis 
Table 4 and 5 show the clinical and laboratory characteristics of all patients. At the 
beginning of the evaluation 40 (27.7%) had not developed complications of cirrhosis and 104 
(72.2%) had one or more of them. 
 
Compensated cirrhosis (yes/no) 40 (27.8%) / 104 (72.2%) 
Presence of varices (yes/no)  96 (66.7%) / 48(33.3%) 
Compensated cirrhosis(yes/no)  15 (37.5%) / 25 (62.5%) 
Decompensated cirrhosis(yes/no) 81(77.8%)/23 (22.1%) 
Child Pugh classification  
A 56 (38.8%) 
B 46(31.94%) 
C 42(29.16%) 
Child - Pugh score 8.02 ± 2.6 
MELD score  13.36 ± 5.74 
Previous encephalopathy (yes/no)  21 (14.65)/123(85.4%) 
Previous ascites (yes/no)  92 (63.9%) / 52 (36.15%) 
Previous variceal bleeding (yes/no) 35 (24.3%) / 109 (75.7%) 
Hepatocellular carcinoma (yes/no) 7 (4.9%) / 137 (95.1%) 
Table 4. Clinical characteristics 
According to Child-Pugh stages predominated A (56 patients, 38.8%), followed by B (46 
patients, 31.9%) and C (42 patients, 29.1%). The average score was 8.02 ± 2.6. The mean 
MELD score was: 13.36 ± 5.74. 
 
Laboratory test  
Bilirubin (μmol/L) 48.06 ± 59.4 
Albumin (g/L) 34.10 ± 8.30 
INR 1.45 ± 0.51 
Creatinine (μmol/L) 83.53 ± 25.35 
Table 5. Laboratory characteristics 
96 patients showed esophageal varices (66.7%). Of these, 15 (37.5%) were in compensated 
stage and 81 (77.8%) in the decompensated one. Of these, 35 (24.3%) had at least one episode 
of gastrointestinal bleeding. 
The most frequent complication was ascites (92 patients, 63.9%), followed by bleeding from 
esophageal varices (35 patients, 24.3%) and hepatic encephalopathy (21 patients, 14.6%). 
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Seven patients were diagnosed with hepatocellular carcinoma during follow-up and in two 
patients who were in Child A stage, it was considered as the cause of decompensation.  
3.1 Survival of patients at three years 
Of the 144 patients studied, 65 (45.1%) died from complications of liver cirrhosis between 
January 2004 and April 2011. Overall survival was 62.5% at three years follow-up, with a 
mean of 48.05 months and 95% between 43.2-52.8 months (see Figure 1). 
As shown in Figure 2 and Table 6, survival of patients with compensated liver cirrhosis was 
85% at three years with a mean of 60.27 months (CI 53.96-66.58). Patients who had 
complications had a survival rate of 53.8% with a mean of 42.4 months (CI 36.59-48.20)  
(p <0.001). Of the patients with compensated liver cirrhosis at a baseline, the seven who died 
during the follow-up period were due to complications of the disease. Two of them 
presented HCC. 
 
Cirrhosis Median (months) CI 95% P 
Compensated 60.27 53.96 – 66.58 p<0.001 
Decompensated 42.40 36.59 – 48.20  
Table 6. Survival of patients with compensated and decompensated liver cirrhosis 
As presented in Table 7, univariate analysis showed continuous variables that were associated 
with significantly poorer survival such as, age of the patients (p = 0.017), bilirubin (p = 0.04), 
albumin (p <0.001 ), the INR (p <0.001), Child-Pugh score (p <0.001) and MELD score  
(p <0.001). Creatinine did not behave the same way (p = 0.779). 
Categorical variables that were associated with a significantly lower survival were, male sex 
(p = 0.033), history of ascites (p = 0,001), of hepatic encephalopathy (p = 0.032), and the 
development of hepatocellular carcinoma (p = 0.003). The bleeding, did not behave the same 
way. (Table 7). 
 
Value Surviving Deceased p 
Patients 79 65  
Sex (male/female) 46/33 48/17 0.033 
Age (years, SD) 45.4 ± 13.2 50.66 ± 12.09 0.017 
Previous ascites (yes/no) 41/38 51/14 0.001 
Previous encephalopathy (yes/no) 7/72 14/51 0.032 
Hepatocellular carcinoma (yes/no) 0/79 7/58 <0.001 
Previous variceal bleeding (yes/no) 18/61 17/48 0.639 
Compensated cirrhosis (yes/no) 32/47 8/57 <0.001 
Bilirubin (µmol/L) 35.18 ± 50.18 63.72 ± 66 0.04 
Albumin (g/L) 37.56 ± 7.74 29.97 ± 7.03 <0.001 
INR 1.31 ± 0.49 1.62 ± 0.49 <0.001 
Creatinine (µmol/L) 84.03 ± 24.6 82.94 ± 26.32 0.779 
Child- Pugh score 7.0 ± 2.1 9.27 ± 2.63 <0.001 
MELD score 11.45 ± 4.99 15.67 ± 5.77 <0.001 
Table 7. Clinical and biochemical characteristics of the 144 cirrhotic patients at 3 years follow-up 
www.intechopen.com
 
Prognostic Factors for Survival in Patients with Liver Cirrhosis 
 
133 
1.0
0.8
0.6
0.4
0.2
0.0
C
u
m
 S
u
r
v
iv
a
l
0            12            24            36           48            60           72            84
survival
62.5%
Survival
Function
Censored+ 
 
Fig. 1. Overall survival 
0             12            24            36            48            60            72            84
survival
1.0
0.8
0.6
0.4
0.2
0.0
C
u
m
 S
u
r
v
iv
a
l
Compensated
no
Yes
no-censored
si-censored
85%
53.8%
 
Fig. 2. Survival of patients with compensated and decompensated liver cirrhosis 
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In the analysis of the survival curves of Kaplan-Meier, categorical variables that had 
significantly lower survival were male gender (56.4%, average 43.69, 47.56-61.0), the history 
of ascites (51.1%, average 41.3 months; 35,06-47.53) hepatic encephalopathy (38.1%, mean 
30.85 months, 17.67, 44.04), the development of hepatocellular carcinoma (0%, average 11.42, 
4.09-18.76) and Child-Pugh stages with 80.8% survival for stage A, 69.9% for B and 31% for 
C (Table 8). Upper gastrointestinal bleeding for varicose veins was not associated with 
survival. 
 
Variable Survival at 36 
months (%) 
Median 
(months) 
CI 95% p 
Sex: Female 74% 54.28 47.56- 61.0 0.033 
Male 56,4 43.69 37.52- 49.87  
Ascites: No 82.7 57.722 51.75- 63.69 0.001 
Yes 51.1 41.300 35.06- 47.53  
Encephalopathy: No 66.7 50.95 45.96- 55.92 0.032 
Yes 38.1 30.85 17,67- 44.04  
Variceal bleeding: No 61.5 47.85 42.23- 53.46 0.639 
Yes 65.7 47.68 38.62- 56.73  
HCC: No 65.7 49.92 45.07-54.77 <0.001 
Yes 0 11.42 4.09-18.76  
Child- Pugh: A 80.8 58,04 52.28-63.81 <0.001 
B 69.6 51.71 44.30-59.13  
C 31.0 26.42 17.88-34.97  
Table 8. Univariate analysis of categorical variables to three years of survival 
 
 Exp(β) p 
Age 1.024 0.029 
HCC 2.377 <0,001 
Child-Pugh 1.378 <0,001 
Table 9. Predictors of survival of liver cirrhosis at 3 years follow- up Cox regression 
4. Discussion 
According to different authors, cirrhosis caused by alcohol and HCV are more frequent in 
the fifth and sixth decades of life, and in males. (Safdar K, 2004; Sagnelli E, 2005; Benvegnù 
L, 2004) Recent series described that the most common causes of liver cirrhosis are due to 
HCV, HBV, and alcoholism. These causes can vary between them by geographic area. 
(Dehesa-Violante M, 2007; Fattovich G, 2008) 
These conclusions coincide in this series, since the average age was 47.8 ± 12.95 years. The 
group more frequent were in patients between 40 to 60 years, male sex and the most 
frequent causes of cirrhosis were HCV and alcohol. 
Cirrhosis is often manifested as a silent disease. In the compensated phase the diagnosis can 
be made by nonspecific manifestations or laboratory findings, whereas in later stages the 
disease may debut by its complications. (Heidelbaugh JJ, 2006) At the beginning of the study 
27.8% of patients were in compensated phase and 72.2% had developed complications. 
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Fig. 3. Survival of patients according the Child-Pugh score 
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Fig. 4. Survival of patients according the diagnosis of hepatocellular carcinoma 
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The presence of esophageal varices was more frequent in decompensated liver cirrhosis. 
Ascites was the most common complication followed by gastrointestinal bleeding, which 
coincides with reports of other authors (Gines P, 1987). As is known, the higher frequency of 
esophageal varices is also associated with ascites and with the advanced stage of Child-
Pugh. (Samada M, 2008; Sarwar S, 2005; Dib N, 2005) 
In this series, overall survival at three years follow-up was 62.5%, which approximates to 
the average values to the review of natural history and survival in cirrhosis of 118 studies 
conducted by D'Amico. (D'Amico G, 2006) They reported on 32 studies of survival, with 
median follow-up of 33 months, cumulative survival of 61%.  
Overall survival is less specific because patients are very heterogeneous regarding the 
presence or absence of complications. In conducting the study it was observed that patients 
that were at the beginning of the evaluation in compensated and decompensated stage, 
presented survival rates with significant differences, with 85% and 53.8% respectively. It is 
reported that the development of hepatocellular carcinoma is a major cause of mortality in 
patients in compensated phase and the transition to the decompensated stage may be 5 to 
7% per year (D'Amico G, 2001). In the present study, HCC was the cause of death in 28.5% 
of patients who were compensated and the rest died of other cirrhosis complications.  
As identified by D'Amico (D'Amico, 2006), compensated cirrhosis by the absence of 
complications includes two states, patients without varices or ascites (state 1) and patients 
with varicose veins but without ascites (state 2). Although they have different prognoses, 
mortality is low (1% per year for state 1 and 3.4% for state 2). On the other hand, 
decompensated cirrhosis (stages 3 and 4) has a significantly higher mortality (20% per year 
for the state 3 and up to 57% in 4). This classification was accepted at the Consensus 
Conference of Portal Hypertension, Baveno IV (De Franchis R, 2000) and modified states 
Baveno decompensated phase V (D 'Amico G, 2011) 
Many factors have been studied in relation to the survival of patients with liver cirrhosis 
and to improve forecasting models. In the study by D'Amico (D'Amico, 2006), it was 
reported that the Child-Pugh was the best predictor of mortality in cirrhosis, followed by 
the five components measured individually. Age was the only variable that was predictive 
of survival in more than 10 studies, and that was not part of the Child-Pugh score. These 
data are consistent with those presented by the authors of this paper. The univariate 
analysis showed that in addition to Child-Pugh, MELD, age, sex and liver cancer were 
associated with lower survival of the five variables of Child-Pugh, bilirubin, albumin, INR 
from prothrombin time, ascites and encephalopathy. 
In our series, creatinine was not a factor associated with survival, which corresponds with 
other authors. (Degre D, 2004; Ruf AE, 2005) In relation to sex as a prognostic factor, we 
must consider that the United States 56 409 deaths related to hepatitis C in the period 1995-
2004, there was an increase in mortality from 1.09 to 2.44 per 100 000 inhabitants. This 
represented an increase of 123% in the period studied, a male predominance with 144% and 
81% in females. Alcohol was a cofactor related and could be underestimated. These data 
confirm the higher male mortality by the two leading causes of cirrhosis, hepatitis C and 
alcohol (Wise M, 2008) 
Ascites is one of the earliest and most frequent complications of liver cirrhosis. 
Approximately 50% of patients with compensated cirrhosis, can develop ascites within 10 to 
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15 years after diagnosis, with a mortality of 15% per year and 44% within five years follow-
up (Planas R, 2006). In this study, the survival at three years follow-up was 51.1%, indicating 
that all patients with ascites should be evaluated for liver transplantation, preferably before 
they develop renal dysfunction, and worsening prognosis.  
Encephalopathy is a complication involving low survival. Bustamante et al. (Bustamante J, 
1999), followed for 12 ± 17 months 111 patients with cirrhosis who had a first episode of 
acute encephalopathy, and found that 74% died during follow-up, with a survival rate of 
42% per year. In this series the survival at three years was 38.1%.  
Hepatocellular carcinoma was the complication that had lower survival; within 11.4 months 
mean follow-up there was no survivor. This complication can occur at any stage of cirrhosis 
and is associated with increased frequency in viral causes, so it is very important to increase 
surveillance programs for early diagnosis and thereby obtain prolonged survivals rates. 
(Capocaccia R, 2007; Perz JF, 2006) In studies of cirrhosis caused by HBV and HCV has been 
the leading cause of mortality, especially in patients with HCV. (Perz JF, 2006) 
In the survival analysis of MELD and Child-Pugh, it was observed that as they grow, the 
rate decreases in relation to time tracking. Although the MELD system is the outcome of 
choice to give priority to patients on the waiting list for liver transplantation in the 
Consensus Document of the Spanish Society for Liver Transplantation published in 2008, it 
is argued that currently there are not available data for the Child-Pugh classification no 
longer used in favor of the MELD system and recommend to apply both models with their 
advantages and limitations in the future to decide which method is most convenient. 
Spanish Society for Liver Transplantation. (Spanish Society for Liver Transplantation, 2008) 
In the work developed in short and long term, the Child-Pugh score has proven to be a good 
predictor of mortality. In a review by Cholongitas (Cholongitas E, 2006) on studies that 
compare the MELD and Child-Pugh, performed with patients on the waiting list for liver 
transplantation that included 12 532 cirrhotic patients, only 4 of 11 studies showed that the 
MELD is superior to Child-Pugh in predicting short-term mortality and Gotthardt et al 
(Gotthardt D, 2009) from the results of their work, consider that for the prediction of long-
term mortality (estimated at one year) and removal from the waiting list of patients awaiting 
transplantation, monitoring should be better by Child-Pugh score than by MELD. This 
might have implications for the development of new improved scoring systems 
In this series, we found on univariate analysis similar significance of Child-Pugh and MELD 
index as predictors of survival at three years follow-up. But the Child-Pugh acted as an 
independent predictor of survival. 
The prediction of MELD can rise to associate other factors such as clinical or biochemicals. 
Some studies have shown the prognostic contribution of the addition of sodium to MELD 
(Ruf AE 2005, Biggins SW 2005), as well as ascites and encephalopathy. (Somsouk M, 2009, 
Stewart CA, 2007) It has been shown that patients with severe ascites and low sodium, low 
MELD even have very poor prognosis and suggest incorporating these two elements to the 
MELD (Heuman DM, 2007).  
In another review of prognostic models for priority to liver transplantation, with numerous 
suggestions for additions to the MELD concluded that the MELD-sodium store is better able 
to predict survival on the waiting list than the Standard MELD score. (Cholongitas E, 2010) 
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Biselli M et al (Biselli M 2010) evaluated the survival of patients with advanced liver 
cirrhosis, liver transplant candidates at 3, 6 and 12 months. Six scoring systems used, 
included the modified Child Pugh (MCTP) and the standard MELD, and four of its 
modifications. The modified CTP (Huo TI, 2006) was obtained by assigning an additional 
point in patients whose serum bilirubin was > 8 mg/dL, prothrombin time prolongation >11 
seconds, or albumin <2.3 g/dL, accordingly a mCTP score of 16-18 was defined as class D, 
which identifies severely decompensated cirrhosis. In this study population, the prognostic 
power of mCTP did not differ from that of MELD, MELD-sodium and integrated MELD 
were the best prognostic models. 
Although these models are used to assess the short-term survival and give priority for liver 
transplantation, it would be interesting to determine their behavior in pursuit of longer than 
one year. 
5. Conclusions 
Age, Child-Pugh score and the development of hepatocellular carcinoma behaved as 
independent predictors of survival within three years of monitoring. 
Undoubtedly, the Child-Pugh has a good long-term predictive capacity and the development 
of hepatocellular carcinoma can vary the prognosis of these patients in the short term, so 
you should keep a surveillance system for early detection.  
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